Personalized Ototoxicity Prevention and Mitigation System

The present invention provides a next-generation system for mitigating ototoxicity associated with platinum-based antineoplastic agents, comprising adaptive, real-time dosing of anti-platinum chemoprotectant agents, personalized to individual subjects' genetic profiles and audiometric responses.

Platinum-based antineoplastic agents, such as cisplatin, are widely used to treat cancers and tumors, but they are known to induce hearing loss in human and animal models. The original patent disclosed hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent to mitigate ototoxicity. However, these compositions have limitations, including fixed dosing regimens and lack of personalization. The present inventive concept addresses these limitations by introducing a system that dynamically adjusts the dosage of anti-platinum chemoprotectant agents based on individual subjects' responses, providing a more effective and personalized approach to ototoxicity prevention and mitigation.

The system comprises a platinum-based antineoplastic agent delivery module and an adaptive, real-time anti-platinum chemoprotectant agent dosing module. The dosing module uses machine learning algorithms to analyze the subject's genetic profile, medical history, and audiometric response to platinum-based antineoplastic agents. Based on this analysis, the module selects an optimal anti-platinum chemoprotectant agent and dosage regimen, which is then administered to the subject. The system may also include a wearable device for monitoring ototoxicity, a computer-implemented method for predicting ototoxicity risk, and a nanoparticle-based delivery system for targeted and sustained release of the anti-platinum chemoprotectant agent.

The present inventive concept introduces a paradigm shift in ototoxicity prevention and mitigation by providing a personalized, adaptive, and real-time approach. The use of machine learning algorithms to analyze individual subjects' responses and adjust dosing regimens is a novel and non-obvious aspect of the invention. Additionally, the integration of wearable devices, computer-implemented methods, and nanoparticle-based delivery systems provides a comprehensive and innovative solution to ototoxicity prevention and mitigation.

Alternative embodiments of the system may include the use of different machine learning algorithms, additional sensors for monitoring ototoxicity, or different types of nanoparticle-based delivery systems. Variations of the system may include the use of different anti-platinum chemoprotectant agents, different dosing regimens, or different methods for predicting ototoxicity risk.

The present inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the areas of oncology and otolaryngology. The system may be marketed as a comprehensive solution for ototoxicity prevention and mitigation, providing a competitive advantage over existing products and treatments. Potential customers may include pharmaceutical companies, hospitals, and clinics, as well as individual patients and healthcare providers.